SCHEMBL6025879

SCHEMBL6025879

O=C(c1ncc(-c2ccc(Cl)cc2)c(-c2ccc(Cl)cc2Cl)n1)N1CCN(c2ccccn2)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 4/20 0.59
ALDH1A1 P00352 9/20 0.53
KDM4E B2RXH2 5/20 0.52
CYP1A2 P05177 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
CCKAR P32238 2/20 0.51
SMN1; SMN2 Q16637 4/20 0.50
HPGD P15428 3/20 0.50
CNR1 P21554 2/20 0.50
TSHR P16473 4/20 0.49
MAPT P10636 3/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
USP2 O75604 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
EPHX2 P34913 1/20 0.49
LMNA P02545 3/20 0.49
HTT P42858 1/20 0.49
MAPK1 P28482 2/20 0.48
MEN1 O00255 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6024742 0.93 HSD17B10 (0.59) HSD17B10ALDH1A1KDM4ECYP1A2CYP2C9
SCHEMBL6812212 0.90 SLC6A7 (0.55) HSD17B10KDM4ECCKARCNR1MAPT
SCHEMBL6025648 0.83 CNR1 (0.56) CCKARCNR1TSHRLMNA
SCHEMBL6807596 0.83 CNR1 (0.71) CNR1MEN1KMT2A
SCHEMBL6026092 0.81 CNR1 (0.56) HSD17B10ALDH1A1KDM4ECCKARSMN1; SMN2
SCHEMBL6025823 0.81 CNR1 (0.56) CCKARCNR1
SCHEMBL6026396 0.81 ALPL (0.54) ALDH1A1KDM4ECCKARCNR1MAPT
SCHEMBL6808103 0.80 CNR1 (0.51) CCKARCNR1
SCHEMBL6025796 0.80 CNR1 (0.58) ALDH1A1CCKARCNR1TSHRLMNA
SCHEMBL6807904 0.79 CNR1 (0.55) ALDH1A1CCKARSMN1; SMN2HPGDCNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040259887-A1 Cannabinoid receptor ligands and uses thereof PFIZER INC 2004-12-23 US claimed
EP-1638570-A1 PYRIMIDINE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS Pfizer Products Inc. (US) 2006-03-29 EP disclosed
US-20040259887-A1 Cannabinoid receptor ligands and uses thereof PFIZER INC 2004-12-23 US disclosed
WO-2004110453-A1 PYRIMIDINE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS PFIZER PRODUCTS INC. (US) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259887-A1 Cannabinoid receptor ligands and uses thereof CNR1, CNR2, GPR18 HSD17B10 2817/4885ALDH1A1 1683/4885KDM4E 3361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.